Economic impact of poor compliance with pharmaceuticals

References

• Stephenson J. Noncompliance may cause half of antihypertensive drug 'failures'. JAMA 282,313–314 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am. J Obstet. Gynecol. 180,276–279 (1999).
   PubMed Web of Science ®Google Scholar
• Metson D. Lessons from an audit of unplanned pregnancies. BT. Med. J 297, 904–906 (1988).
   PubMedGoogle Scholar
• Chisholm MA. Issues of adherence to immunosuppressant therapy after solid-organ transplant. Drugs 62,567–575 (2002).
   Google Scholar
• Hughes DA, Bagust A, Haycox A, Walley T Accounting for noncompliance in pharmacoeconomic evaluations. PhalmacoEconomics 19,1185–1197 (2001).
   PubMed Web of Science ®Google Scholar
• Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medications in primary care. BT. Med. J. 307, 846–848 (1993).
   Google Scholar
• Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug- Info. J. 22,363–378 (1988).
   Google Scholar
• Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Gun. Pharmacokinet. 32, 345–356 (1997).
   Google Scholar
• •Compelling review of the patterns of dose taking and the clinical consequences of noncompliance as assessed by electronic means.
   Google Scholar
• Claxton AJ, Cramer JA, Pierce C. A systematic review of the association between dose regimens and medication compliance. Gun. Ther. 23, 1296–1310 (2001).
   Google Scholar
• Jones JK, Gorkin L, Dan JK et al Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BT. Merl. J. 311, 293–295 (1995).
   PubMed Web of Science ®Google Scholar
• Maronde RF, Chan LS, Larsen FJ, Strandberg LR, Laventurier ME, Sullivan SR. Underutilization of antihypertensive drugs and associated hospitalization. Merl. Cam 27,1159–1166 (1989).
   Google Scholar
• Skaer TL, Sclar DA, Robison LM. Noncompliance with antihypertensive therapy. Economic consequences. PharmacoEconomics 9,1–4 (1996).
   Google Scholar
• Oster G, Borok GM, Menzin J etal. Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch. Intern. Merl. 156,731-739 (1996).
   Google Scholar
• Simmons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med. J. Aust. 164, 208–211 (1996).
   Google Scholar
• Avorn J, Monette J, Lacour A etal. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279, 1458–1462 (1998).
   PubMed Web of Science ®Google Scholar
• Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. AIR I Manag. Care 5, 437–444 (1999).
   Google Scholar
• Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin re-uptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BE Med. J. 310, 1433–1438 (1995).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can. Med. ASS.J 160, 41–46 (1999).
   Google Scholar
• Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using 'real world' randomized trials: The case of new antidepressant drugs." Clin. Epidemial 48, 363–373 (1995).
   Google Scholar
• Payers PM, Hand DJ. Generalisation from Phase III clinical trials: survival, quality of life and health economics. Lancet 350, 1025–1027 (1997).
   PubMed Web of Science ®Google Scholar
• Andrade SE, Saperia GM, Berger ML, Platt R. Effectiveness of antihyperlipidemic drug management in clinical practice. Clin. Ther. 21, 1973–1987 (1999).
   Google Scholar
• Andrade SE, Walker AM, Gottlieb LK et al Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl Med 332, 1125–1131 (1995).
   PubMed Web of Science ®Google Scholar
• Revicki DA, Frank L. Pharmacoeconomic evaluations in the real world. Effectiveness versus efficacy studies. PharmacoEconomics 15, 423–434 (1999).
   PubMed Web of Science ®Google Scholar
• •Comprehensive introduction to the limitations of randomized controlled trials in capturing real-world effectiveness data.
   Google Scholar
• Boudes P Drug compliance in therapeutic trials: A review. Cont. Clin. Trials 19, 257–268 (1998).
   Google Scholar
• Paes AHP, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm. World Sci. 20, 73–77 (1998).
   PubMed Web of Science ®Google Scholar
• Rudd P, Byyny RL, Zachary Vet al. The natural history of medication compliance in a drug trial: Limitations of pill counts. Clin. Pharmacol Ther. 46, 169–176 (1989).
   Google Scholar
• Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin. Pharmacol Ther. 46, 163–168 (1989).
   Google Scholar
• •Highlights the gross overestimation of compliance when tablet counts are taken as a measure of dosing history
   Google Scholar
• Metry J-M, Meyer UA. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. John Wiley, Chichester, UK (1999).
   Google Scholar
• •Essential reference which provides valuable insights to all aspects of drug regimen compliance.
   Google Scholar
• Urquhart J. Ascertaining how much compliance is enough with out-patient antibiotic regimens. Postgrad. Med. J. 68\(Suppl. 3), S49—S59 (1992).
   Google Scholar
• Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of 0-blockers. JAMA 263, 1653–1657 (1990).
   Google Scholar
• Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105, 1446–1452 (2002).
   PubMed Web of Science ®Google Scholar
• Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 276, 1955–1966 (1996).
   Google Scholar
• Urquhart J. Erratic compliance with prescribed drug regimens:Target for drug delivery systems. Clin. Pharmacol Themp. 67, 331–334 (2000).
   Google Scholar
• Young A, Haddad P. Discontinuation symptoms and psychotropic drugs. Lancet 355, 1184 (2000).
   Google Scholar
• Hughes DA, Bagust A, Haycox A, Walley T The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature. Health Econ. 10, 601–615 (2001).
   PubMed Web of Science ®Google Scholar
• Geng M, Mardh P-A. Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis. PharmacoEconomics 12, 374–383 (1997).
   Google Scholar
• Scott LL, Alexander J. Cost-effectiveness of acyclovir suppression to prevent recurrent genital herpes in term pregnancy. Am J. Per/natal. 15, 57–62 (1998).
   PubMed Web of Science ®Google Scholar
• Clark WF, Churchill DN, Forwell L. Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. Can. Med Assoc. 162, 195–198 (2000).
   Google Scholar
• Taylor JL, Zagari M, Murphy K, Freston JW. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch. Intern. Med. 157, 87–97 (1997).
   PubMedGoogle Scholar
• Glazer WM, Ereshefsky L. A pharmacoeconomic model of out-patient antipsychotic therapy in 'revolving door' schizophrenic patients. J. Clin. Psychiatry 57, 337–345 (1996).
   PubMed Web of Science ®Google Scholar
• Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counselling. JAMA 275, 1247–1251 (1996).
   PubMed Web of Science ®Google Scholar
• Vakil N, Fennerty MB. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am. J. Gastroenterol 91, 239–245 (1996).
   PubMed Web of Science ®Google Scholar
• Haddix AC, Hillis SD, Kassler WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sexually 7ians. Dis. 22, 274–280 (1995).
   Google Scholar
• Brown RE, Kendall MJ, Halpern MT Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis. J. Clin. Pharm. Ther 22, 67–76 (1997).
   PubMed Web of Science ®Google Scholar
• Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J. Clin. Psychiatry 58, 47–58 (1997).
   PubMed Web of Science ®Google Scholar
• Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with Type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann. Intern Med. 131, 707–708 (1999).
   Google Scholar
• Lafata JE, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J. Gen. Intern. Med. 15, 31–37 (2000).
   PubMed Web of Science ®Google Scholar
• Rosner AJ, Grima DT, Torrance GW etal. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. PharmacoEconomics 14, 559–573 (1998).
   Google Scholar
• Rocchi A, Tingey D. Economic evaluation of dorzolamide vs. pilocarpine for primary open-angle glaucoma. Can. J. OphthaImol. 32,414–418 (1997).
   Google Scholar
• Wasley MA, McNagny SE, Phillips VL, Ahluwalia JS. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Preventive Med. 26,264–270 (1997).
   PubMed Web of Science ®Google Scholar
• Moore RD, Chaisson RE. Cost utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. Acquit: Immune Defic. Synth: Hum. Retrovirol 16,15–21 (1997).
   Google Scholar
• Brown MG, Murray TJ, Fisk JD, Sketris IS, Schwartz CE, LeBlanc JC. A therapeutic and economic assessment of Betaseron0 in multiple sclerosis. Canadian Co-ordinating Office for Health Technology Assessment, Ottawa, Canada (1996).
   Google Scholar
• Brown MCJ, Nimmerrichter AA, Guest JE Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria. Eur PTchiatr 14, 230–244 (1999).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model. Neurourol Umdy7amics17, 599–611 (1998).
   Google Scholar
• Lapierre Y, Bentkover J, Schainbaum S, Manners S. Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. Can. J. fisychtt: 40,370-377 (1995).
   Google Scholar
• Plans-Rubio, P. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease; evaluative study carried out in Spain. PharmacoEconomics 13,623–643 (1998).
   Google Scholar
• Garton MJ, Cooper C, Reid D. Perimenopausal bone density screening - will it help prevent osteoporosis? Matutitas 26,35–43 (1997).
   Google Scholar
• Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. PharmacoEconomics 15, 217–228 (1999).
   PubMed Web of Science ®Google Scholar
• Boissel J-P, Nony P Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance. Clin. Pharmacokinetics 41, 1–6 (2002).
   Web of Science ®Google Scholar
• Wahl LM, Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proc. R. Soc. Land. B. 267, 835–843 (2000).
   PubMed Web of Science ®Google Scholar
• Hughes DA, Bagust A, Haycox A, Walley T The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies. Val. Health 3, 373 (2000).
   Google Scholar
• Buxton MJ, Drummond ME, Van Hout BA et al. Modelling in economic evaluation: An unavoidable fact of life. Health Econ. 6, 217–227 (1997).
   PubMed Web of Science ®Google Scholar